Novartis Stresses FDA Approvals In Zometa Trial

Law360, New York (May 1, 2013, 8:45 PM EDT) -- Novartis Pharmaceuticals Corp. on Wednesday tried to use a plaintiff's expert in New Jersey mass tort litigation over its bone drug Zometa to underscore U.S. Food and Drug Administration approvals for the medication and the company's own efforts to report cases of dead jaw bone to the regulator.

Testifying for plaintiff Beverly Meng, regulatory and labeling expert Dr. Suzanne Parisian told jurors in Middlesex County Superior Court that labels for Zometa failed to provide adequate notice about the risks of osteonecrosis of the jaw, or ONJ,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.